English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The aim of the study was to profile those patients included in\udthe RELESSER registry with histologically proven renal involvement\udin order to better understand the current state of lupus nephritis (LN) in\udSpain.\udRELESSER-TRANS is a multicenter cross-sectional registry with\udan analytical component. Information was collected from the medical\udrecords of patients with systemic lupus erythematosus who were\udfollowed at participating rheumatology units. A total of 359 variables\udincluding demographic data, clinical manifestations, disease activity,\udseverity, comorbidities, LN outcome, treatments, and mortality were\udrecorded. Only patients with a histological confirmation of LN were\udincluded.We performed a descriptive analysis, chi-square or Student?s t\udtests according to the type of variable and its relationship with LN. Odds\udratio and confidence intervals were calculated by using simple logistic\udregression.\udLN was histologically confirmed in 1092/3575 patients (30.5%).\udMost patients were female (85.7%), Caucasian (90.2%), and the mean\udage at LN diagnosis was 28.4 12.7 years. The risk for LN development\udwas higher in men (M/F:47.85/30.91%, P<0.001), in younger individuals\ud(P<0.001), and in Hispanics (P¼0.03). Complete response to\udtreatment was achieved in 68.3% of patients; 10.35% developed ESRD,\udwhich required a kidney transplant in 45% of such cases. The older the\udpatient, the greater was the likelihood of complete response (P<0.001).\udRecurrences were associated with persistent lupus activity at the time of\udthe last visit (P<0.001) and with ESRD (P<0.001). Thrombotic\udmicroangiopathy was a risk factor for ESRD (P¼0.04), as for the\udnecessity of dialysis (P¼0.01) or renal transplantation (P¼0.03). LN\uditself was a poor prognostic risk factor of mortality (OR 2.4 [1.81?3.22],\udP<0.001). Patients receiving antimalarials had a significantly lower\udrisk of developing LN (P<0.001) and ESRD (P<0.001), and\udresponded better to specific treatments for LN (P¼0.014).\udMore than two-thirds of the patients with LN from a wide\udEuropean cohort achieved a complete response to treatment. The\udpresence of positive anti-Sm antibodies was associated with a higher\udfrequency of LN and a decreased rate of complete response to treatment.\udThe use of antimalarials reduced both the risk of developing renal\uddisease and its severity, and contributed to attaining a complete renal\udresponse

medicine

Characterization of Patients With Lupus Nephritis Included in a Large Cohort From the Spanish Society of Rheumatology Registry of Patients With Systemic Lupus Erythematosus (RELESSER)